Do EPA and DHA supply the substrates for specialized pro-resolving mediators and does low omega‑3 reduce inflammation resolution?

The conversion of omega-3 fatty acids into specialized pro-resolving mediators (SPMs) is a fundamental biological process for terminating inflammation and restoring tissue homeostasis. Substantial evidence confirms that EPA and DHA serve as the essential metabolic substrates for these mediators, and insufficient levels of these fatty acids can impair the body's natural "off switch" for inflammatory responses.

Mechanistic basis for resolution

SPMs, including resolvins (E and D series), protectins, and maresins, are not passive byproducts but active signaling molecules.

• Substrate Availability: EPA and DHA are converted into SPMs via highly regulated enzymatic pathways involving COX-2, 5-LOX, 12-LOX, and 15-LOX. When omega-3 status is low, the synthesis of these mediators is stoichiometrically limited.
• Receptor Signaling: SPMs signal through specific G protein-coupled receptors (GPCRs), such as ALX/FPR2. This signaling actively stops the influx of neutrophils (white blood cells) into tissues and downregulates endothelial adhesion molecules that otherwise sustain inflammation.
• Efferocytosis: A hallmark of SPM action is the enhancement of "efferocytosis"—the process by which macrophages identify and ingest dead cells and debris. This is critical for preventing tissue damage and promoting repair.

Clinical and physiological implications

A low omega-3 status creates a biochemical environment where inflammation may become chronic rather than self-resolving.

• Inflammatory Dominance: Omega-3s compete with omega-6 arachidonic acid (AA) for enzymatic processing. When omega-3 levels are low, AA-derived pro-inflammatory eicosanoids predominate, potentially extending the duration of inflammatory events.
• Systemic Markers: Research consistently shows an inverse relationship between the Omega-3 Index (the percentage of EPA and DHA in red blood cell membranes) and systemic inflammatory markers like C-reactive protein (CRP) and IL-6. For example, lower omega-3 levels are frequently associated with higher baseline CRP in aging populations and those with cardiovascular conditions.
• Aspirin Interaction: Low doses of aspirin can acetylate COX-2, triggering the production of "aspirin-triggered" SPMs (AT-SPMs). These versions are more resistant to metabolic breakdown, highlighting a unique synergy between omega-3 status and aspirin therapy in promoting resolution.

Bottom line

Omega-3 fatty acids are the vital building blocks for specialized mediators that actively "turn off" inflammation. Low omega-3 status reduces the capacity for this resolution (catabasis), potentially leading to prolonged or chronic inflammatory states. Maintaining an adequate Omega-3 Index is essential for providing the substrates necessary to orchestrate tissue repair and homeostasis.